CBER’s New Director “Marks” A New Era For Biologics Regulation
This article was originally published in RPM Report
Executive Summary
Peter Marks takes over the top spot in the center for biologics at FDA after a four year training period as deputy director. His background appears well suited to what promises to be a transformative era in medicine.
You may also be interested in...
FDA's Califf Seeks His First Big Hire: Chief Scientist
The US agency seeks candidates for the executive position in charge of its research policy apparatus.
FDA Chief Scientist Post A Chance For Califf To Make Mark
Agency seeks candidates for the executive position in charge of its research policy apparatus.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.